Is recurrent hepatitis C worse with living donors?

Current Opinion in Organ Transplantation

Volumn 14, Issue 3, 2009, Pages 240-244

  Kuo, Alexander ^a   Terrault, Norah A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Deceased donor liver transplantation; Hepatitis C virus; Living donor liver transplantation; Recurrence

Indexed keywords

CADAVER DONOR; DISEASE SEVERITY; GRAFT SURVIVAL; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; LIVING DONOR; RECURRENT INFECTION; REVIEW; ADULT; BIOPSY; HOSPITALIZATION; PATIENT SELECTION; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; BIOPSY; GRAFT SURVIVAL; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; PATIENT SELECTION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651037465     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832b1f1d     Document Type: Review

References (21)

1. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006; 6:449-458.
2. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684. (Pubitemid 30180389)
3. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896. (Pubitemid 34267271)
4. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9:S1-S9. (Pubitemid 37407996)
5. Everson GT, Trotter J. Role of adult living donor liver transplantation in patients with hepatitis C. Liver Transpl 2003; 9 (10 Suppl 2):S64-S68. (Pubitemid 37304451)
6. Schiano TD, Gutierrez JA, Walewski JL, et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005; 42:1420-1428.
7. Honda M, Kaneko S, Matsushita E, et al. Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. Gastroenterology 2000; 118:152-162. (Pubitemid 30020383)
8. Yersiz H, Renz JF, Farmer DG, et al. One hundred in situ split-liver transplantations: a single-center experience. Ann Surg 2003; 238:496-505; discussion 506-507. (Pubitemid 38176387)
9. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003; 9:1028-1035. (Pubitemid 37304457)
10. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40:699-707. (Pubitemid 39265593)
11. Thuluvath PJ, Yoo HY. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation. Liver Transpl 2004; 10:1263-1268.
12. Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis Cvirus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13:122-129. Study from the A2ALL Study Cohort showed that reduced graft survival in HCV-positive LDLT recipients was due to center experience. After the first 20 LDLTs from each center were excluded was the analysis, there was no difference in graft survival compared with HCV-positive DDLT.
13. Russo MW, Galanko J, Beavers K, et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004; 10:340-346. (Pubitemid 38380305)
14. Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004; 10:1248-1255. (Pubitemid 39406078)
15. Maluf DG, Stravitz RT, Cotterell AH, et al. Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant 2005; 5:149-156. (Pubitemid 40095140)
16. Guo L, Orrego M, Rodriguez-Luna H, et al. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006; 12:560-565.
17. Schmeding M, Neumann UP, Puhl G, et al. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl 2007; 13:687-692. Study from Berlin using protocol liver biopsies compared 20 LDLT and 269 DDLT recipients. No difference in fibrosis stage at 12 months. No difference in graft survival at 1, 3, and 5 years when patients with hepatocellular carcinoma (HCC) outside of Milan criteria were excluded. (Pubitemid 46796540)
18. Bozorgzadeh A, Jain A, Ryan C, et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. Transplantation 2004; 77:1066-1070. (Pubitemid 38508925)
19. Rodriguez-Luna H, Vargas HE, Sharma P, et al. Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci 2004; 49:38-41. (Pubitemid 38183742)
20. Humar A, Horn K, Kalis A, et al. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant 2005; 5:399-405.
21. Selzner N, Girgrah N, Lilly L, et al. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl 2008; 14:1778-1786. This paper describes the first study to show slower fibrosis progression from HCV recurrence in LDLT vs. DDLT. Authors suggested this was probably due to younger donor age.